You have 9 free searches left this month | for more free features.

Locally advanced clear cell renal cell carcinoma

Showing 1 - 25 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Kidney Cancer Trial in Houston (Axitinib)

Active, not recruiting
  • Kidney Cancer
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Sep 2, 2022

Clear Cell Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma Metastatic Trial in Iowa City (Selenomethionine (SLM),

Recruiting
  • Clear Cell Renal Cell Carcinoma
  • Clear Cell Renal Cell Carcinoma Metastatic
  • Selenomethionine (SLM)
  • +2 more
  • Iowa City, Iowa
    University of Iowa Hospitals & Clinics
Sep 19, 2022

Clear Cell Renal Cell Carcinoma Trial in Houston (Sitravatinib, Nivolumab)

Active, not recruiting
  • Clear Cell Renal Cell Carcinoma
  • Houston, Texas
    MD Anderson Cancer Center
Apr 27, 2021

Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma Trial in Tianjin (Pembrolizumab, Axitinib)

Not yet recruiting
  • Renal Cell Carcinoma
  • Clear Cell Renal Cell Carcinoma
  • Tianjin, Tianjin, China
    Tianjin Medical Unversity Second Hospital
Jul 30, 2021

Locally Advanced or Metastatic Renal Cell Carcinoma Trial in Worldwide (Cabozantinib)

Active, not recruiting
  • Locally Advanced or Metastatic Renal Cell Carcinoma
  • Salzburg, Austria
  • +39 more
Jan 18, 2023

Renal Cell Carcinoma, Papillary Renal Cell Carcinoma Type 1, Papillary Renal Cell Carcinoma Type 2 Trial in Australia

Recruiting
  • Renal Cell Carcinoma
  • +5 more
  • Albury, New South Wales, Australia
  • +10 more
Feb 14, 2022

Locally Advanced and/or Metastatic Anaplastic Large Cell Lymphoma, Locally Advanced and/or Metastatic Inflammatory

Active, not recruiting
  • Locally Advanced and/or Metastatic Anaplastic Large Cell Lymphoma
  • +5 more
  • Crizotinib (PF-02341066)
  • Brussels, Belgium
  • +24 more
May 9, 2022

Clear Cell Renal Cell Carcinoma?Resistance to Immunotherapy Trial in Shanghai (AK104(anti-PD-1/CTLA-4 bi-specific antibody

Recruiting
  • Clear Cell Renal Cell Carcinoma、Resistance to Immunotherapy
  • AK104(anti-PD-1/CTLA-4 bi-specific antibody ,intravenously),lenvatinib( targeted VEGFR 1-3、FGFR、PDGFRα, small molecule TKI,orally
  • Shanghai, Shanghai, China
    Shanghai Renji Hospital
Sep 12, 2023

ccRCC, Clear Cell Renal Cell Carcinoma, Kidney Cancer Trial (NKT2152, palbociclib, sasanlimab)

Not yet recruiting
  • ccRCC
  • +20 more
  • (no location specified)
Jul 6, 2023

Tumors, Kidney Tumors, Urologic Tumors Trial in Nanjing (Toripalimab, Axitinib, Lenvatinib)

Recruiting
  • Neoplasms
  • +12 more
  • Nanjing, Jiangsu, China
    Jinling Hospital, Affiliated Hospital of Medical School, Nanjing
Oct 28, 2023

Renal Cell Carcinoma Trial (HS-10516)

Not yet recruiting
  • Renal Cell Carcinoma
  • (no location specified)
Sep 24, 2023

Renal Cell Carcinoma Trial (Sunitinib)

Not yet recruiting
  • Renal Cell Carcinoma
  • (no location specified)
Sep 11, 2023

Renal Cell Carcinoma Trial in Houston (Tivozanib, Nivolumab)

Not yet recruiting
  • Renal Cell Carcinoma
  • Houston, Texas
    M D Anderson Cancer Center
Sep 19, 2023

Advanced Clear Cell Renal Carcinoma (Ccrcc), Papillary Renal Cell Carcinoma (Prcc) Trial run by the National Cancer Institute

Not yet recruiting
  • Advanced Clear Cell Renal Carcinoma (Ccrcc)
  • Papillary Renal Cell Carcinoma (Prcc)
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Feb 2, 2023

Moesin Expression in Clear Cell Renal Cell Carcinoma

Completed
  • Renal Cell Carcinoma
  • Immunohistochemical detection of Moesin in Clear cell Renal Cell Carcinoma
  • (no location specified)
Sep 20, 2023

Non-Clear Cell Renal Cell Carcinoma Trial in Duarte (XL092, Nivolumab, Sunitinib Malate)

Recruiting
  • Non-Clear Cell Renal Cell Carcinoma
  • Duarte, California
    Exelixis Clinical Site #1
Jan 13, 2023

Renal Cell Carcinoma Trial (Pembrolizumab)

Completed
  • Renal Cell Carcinoma
  • Pembrolizumab
  • (no location specified)
Aug 17, 2022

Clear Cell Renal Cell Carcinoma Trial in Beijing (68Ga-NY104 PET/CT)

Not yet recruiting
  • Clear Cell Renal Cell Carcinoma
  • 68Ga-NY104 PET/CT
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
May 18, 2023

Renal Cell Carcinoma Trial in Beijing, Seoul (RO7247669, Tiragolumab, Pembrolizumab)

Recruiting
  • Renal Cell Carcinoma
  • Beijing, China
  • +1 more
Mar 28, 2023

Metastatic Clear Cell Renal Cell Carcinoma Trial in Beijing (68Ga-NY104 PET/CT)

Not yet recruiting
  • Metastatic Clear Cell Renal Cell Carcinoma
  • 68Ga-NY104 PET/CT
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
May 18, 2023

Advanced Cancer, Clear Cell Renal Cell Carcinoma Trial in Houston (177Lu girentuximab, Nivolumab, Cabozantinib)

Not yet recruiting
  • Advanced Cancer
  • Clear Cell Renal Cell Carcinoma
  • 177Lu girentuximab
  • +3 more
  • Houston, Texas
    MD Anderson Cancer Center
Dec 15, 2022

Clear Cell Renal Cell Carcinoma, Suspected Recurrent Renal Clear Cell Carcinoma, Recurrent Renal Cell Cancer Trial

Not yet recruiting
  • Clear Cell Renal Cell Carcinoma
  • +2 more
  • (no location specified)
May 14, 2023

Clear Cell Renal Cell Carcinoma Trial in Beijing (68Ga-NY104 PET/CT)

Not yet recruiting
  • Clear Cell Renal Cell Carcinoma
  • 68Ga-NY104 PET/CT
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
May 28, 2023

Clear Cell Renal Cell Carcinoma Trial in Los Angeles (89Zr-DFO-girentuximab)

Available
  • Clear Cell Renal Cell Carcinoma
  • 89Zr-DFO-girentuximab
  • Los Angeles, California
    UCLA
Oct 12, 2023